Trials / Completed
CompletedNCT00497991
Safety, Tolerability, PK and Efficacy of AZD1152 in Patients With Relapsed Acute Myeloid Leukemia
A Phase I/II, Open Label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of AZD1152 in Patients With Acute Myeloid Leukaemia.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 65 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess safety and tolerability of multiple ascending doses of AZD1152 and to assess effect of AZD1152 on the rate of complete remission in patients with relapsed acute myeloid leukaemia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AZD1152 |
Timeline
- Start date
- 2006-05-01
- Primary completion
- 2009-10-01
- Completion
- 2010-04-01
- First posted
- 2007-07-09
- Last updated
- 2010-12-08
Locations
10 sites across 4 countries: United States, France, Italy, Netherlands
Source: ClinicalTrials.gov record NCT00497991. Inclusion in this directory is not an endorsement.